Potential drug-drug interactions in the psychiatric hospital: Frequency analysis

Abstract

Citation: Kirilochev OO, Dorfman IP, Umerova AR, Bataeva SE (2019) Potential drug-drug interactions in the psychiatric hospital: Frequency analysis. Research Results in Pharmacology 5(4): 1-6. https://doi. AbstractIntroduction: Drug-drug interactions are an important clinical problem in pharmacotherapy. This study is focused on different types of drugs used in a psychiatric hospital. Materials and methods:The pharmacoepidemiological study included the analysis of medical records of 500 psychiatric inpatients. The patients were divided into 2 groups: under 65 and over 65 years of age. All the drug prescriptions were analyzed to identify the combinations of drugs that can induce drug-drug interactions and determine their clinical significance.Results and discussion: Over 77% of hospitalized patients were administered drug combinations that could induce drug-drug interactions, most of which were of moderate clinical significance. A reliable association was found between the patient's age, the clinical significance of drug-drug interactions, and the pharmacotherapy structure. The most common irrational drug combinations were identified.Conclusion: Timely analysis of drug prescriptions for potential drug-drug interactions can enhance the safety of pharmacotherapy and decrease the risk of adverse drug reactions in the psychiatric inpatient setting. Keywordsadverse drug reactions, drug-drug interactions, pharmacotherapy safety. Copyright Kirilochev OO et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Research Results in Pharmacology 5(4): 1-6 UDC: 615.065

Medication‐related problems in geriatric psychiatry—a retrospective cohort study

“…Other authors, by contrast, have only dealt with subsets of MRPs in psychiatric inpatients, such as drug–drug interactions. For instance, Kirilochev and colleagues found that 77.2% of psychiatric inpatients (386/500) were affected by potential drug–drug interactions, 22 which is comparable to the figures detected in our study (84.3% and 36.5% of patients affected by pharmacodynamic and pharmacokinetic drug interactions, respectively). Of note, the patients in the Kirilochev et al.…”

Assessment of potential drug interactions among psychiatric inpatients receiving antipsychotic therapy of a secondary care hospital, United Arab Emirates

“…[ 17 ] DDIs between olanzapine and haloperidol are known to increase the risk of developing EPS. [ 28 ] Other studies have documented most common pDDIs between haloperidol and trihexyphenidyl (72 [5.3%]),[ 21 ] amitriptyline and fluoxetine (24.5%),[ 22 ] and antipsychotics and beta-blockers. [ 29 ] The difference in these findings could be due to divergences in the study setting, duration, and mainly the study population included.…”

“…documented the number of medications as the most significant predictor of DDIs in patients with mild dementia,[ 34 ] while other studies reported predictors such as prescribed medications,[ 22 ] race and female sex,[ 28 ] and patient's age. [ 21 ]…”

“…[ 18 19 ] There are few studies assessing solely the nature of pDDIs in psychiatric settings. [ 20 21 22 ] Tobacco smoking is common among patients receiving psychotropic medications, consequently reducing the plasma concentrations of the drugs,[ 23 ] while enhanced central nervous system suppression resulting in impaired concentration, coordination, hypotension, and increased sedation is documented with alcohol and antipsychotics. [ 24 ]…”

The pharmacoepidemiology of potential drug-drug interactions in patients with psychiatric disorders

“…Превалирование потенциальных "Serious" и "Monitor Closely" межлекарственных взаимодействий между соматическими препаратами у пациентов старше 65 лет, по всей видимости, связано с наличием сопутствующей патологии в пожилом возрасте и, как следствие, изменением фармакологической структуры лекарственных препаратов, участвующих во взаимодействиях. Зафиксированные данные в целом коррелируют с результатами, полученными нами в исследовании, в котором применялся другой инструмент по выявлению нерациональных комбинаций -Drug Interaction Checker интернет-ресурса drugs.com, информация в котором согласована с официальными инструкциями к лекарственным препаратам, утверждёнными Food and Drug Administration (FDA) [16].…”